AI Article Synopsis
- Glioblastoma (GBM) is a highly aggressive brain tumor with no effective treatments currently available, spurring interest in innovative therapies.
- Recent developments in immuno-virotherapy and the FDA approval of T-VEC have fueled optimism for using oncolytic herpes simplex viruses (oHSVs) as potential GBM treatments.
- The review examines the progress made with oHSV therapies in GBM, highlights existing challenges, and explores strategies to address these issues.
Article Abstract
Glioblastoma (GBM) is a lethal primary malignant brain tumor with no current effective treatments. The recent emergence of immuno-virotherapy and FDA approval of T-VEC have generated a great expectation towards oncolytic herpes simplex viruses (oHSVs) as a promising treatment option for GBM. Since the generation and testing of the first genetically engineered oHSV in glioma in the early 1990s, oHSV-based therapies have shown a long way of great progress in terms of anti-GBM efficacy and safety, both preclinically and clinically. Here, we revisit the literature to understand the recent advancement of oHSV in the treatment of GBM. In addition, we discuss current obstacles to oHSV-based therapies and possible strategies to overcome these pitfalls.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917312 | PMC |
| http://dx.doi.org/10.2147/OV.S268426 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!